Skip to main content
Erschienen in: Breast Cancer 2/2017

11.04.2016 | Original Article

N-acetyltransferase 2 polymorphism and breast cancer risk with smoking: a case control study in Japanese women

verfasst von: Akio Hara, Naruto Taira, Taeko Mizoo, Keiko Nishiyama, Tomohiro Nogami, Takayuki Iwamoto, Takayuki Motoki, Tadahiko Shien, Junji Matsuoka, Hiroyoshi Doihara, Setsuko Ishihara, Hiroshi Kawai, Kensuke Kawasaki, Youichi Ishibe, Yutaka Ogasawara, Shinichiro Miyoshi

Erschienen in: Breast Cancer | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Recent studies have suggested that the association between smoking and breast cancer risk might be modified by polymorphisms in the N-acetyltransferase 2 gene (NAT2). Most of these studies were conducted in Western countries, with few reports from East Asia.

Methods

We conducted a case–control study of 511 breast cancer cases and 527 unmatched healthy controls from December 2010 to November 2011 in Japan. Unconditional logistic regression was used to analyze the association of smoking with breast cancer risk stratified by NAT2 phenotype.

Results

In this population, 11 % of the cases and 10 % of the controls were classified as a slow acetylator phenotype. Compared to never smokers, current smokers had an increased breast cancer risk in multivariate analysis [odds ratio (OR) = 2.27, 95 % confidence interval (95 %CI) = 1.38–3.82]. Subgroup analyses of menopausal status indicated the same tendency. Subgroup analyses of NAT2 phenotype, the ORs in both of rapid and slow acetylator phenotype subgroups were comparable, and no interactions were observed between smoking status and NAT2 phenotype (p = 0.97). A dose-dependent effect of smoking on breast cancer risk was seen for the rapid acetylator phenotype, but not for the slow acetylator phenotype.

Conclusion

Given the high frequency of the rapid acetylator phenotype, these results show that smoking is a risk factor for breast cancer among most Japanese women. It may be of little significance to identify the NAT2 phenotype in the Japanese population.
Literatur
1.
Zurück zum Zitat International Agency for Research on Cancer. Personal habits and indoor combustions. IARC monographs on the evaluation of carcinogenic risks to humans, vol 100E. Lyon: International Agency for Research on Cancer; 2012. pp. 93. International Agency for Research on Cancer. Personal habits and indoor combustions. IARC monographs on the evaluation of carcinogenic risks to humans, vol 100E. Lyon: International Agency for Research on Cancer; 2012. pp. 93.
2.
Zurück zum Zitat Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG, Chang-Claude J. Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17:15–26.CrossRefPubMed Ambrosone CB, Kropp S, Yang J, Yao S, Shields PG, Chang-Claude J. Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17:15–26.CrossRefPubMed
3.
Zurück zum Zitat Cox DG, Dostal L, Hunter DJ, Marchand LL, Hoover R, Ziegler RG, et al. N-acetyltransferase 2 polymorphisms, tobacco smoking and breast cancer in the breast and prostate cancer cohort consortium. Am J Epidemiol. 2011;174:1316–22.CrossRefPubMedPubMedCentral Cox DG, Dostal L, Hunter DJ, Marchand LL, Hoover R, Ziegler RG, et al. N-acetyltransferase 2 polymorphisms, tobacco smoking and breast cancer in the breast and prostate cancer cohort consortium. Am J Epidemiol. 2011;174:1316–22.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokin. 2012;27:9–54.CrossRef Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokin. 2012;27:9–54.CrossRef
5.
Zurück zum Zitat Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 2008;9:21.CrossRefPubMedPubMedCentral Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 2008;9:21.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA. 1996;276:1494–501.CrossRefPubMed Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, Vena JE, Brasure JR, et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA. 1996;276:1494–501.CrossRefPubMed
7.
Zurück zum Zitat Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia-Closas M, Spiegelman D, et al. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis. 1997;18:2127–32.CrossRefPubMed Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia-Closas M, Spiegelman D, et al. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis. 1997;18:2127–32.CrossRefPubMed
8.
Zurück zum Zitat Millikan RC, Pittman GS, Newman B, Tse CJ, Selmin O, Rockhill B, et al. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998;7:371–8.PubMed Millikan RC, Pittman GS, Newman B, Tse CJ, Selmin O, Rockhill B, et al. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998;7:371–8.PubMed
9.
Zurück zum Zitat Morabia A, Bernstein MS, Bouchardy I, Kurtz J, Morris MA. Breast cancer and active and passive smoking: the role of the N-acetyltransferase 2 genotype. Am J Epidemiol. 2000;152:226–32.CrossRefPubMed Morabia A, Bernstein MS, Bouchardy I, Kurtz J, Morris MA. Breast cancer and active and passive smoking: the role of the N-acetyltransferase 2 genotype. Am J Epidemiol. 2000;152:226–32.CrossRefPubMed
10.
Zurück zum Zitat Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, et al. Genetic susceptibility to breast cancer in french-canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer. 2001;92:220–5.CrossRefPubMed Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, et al. Genetic susceptibility to breast cancer in french-canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int J Cancer. 2001;92:220–5.CrossRefPubMed
11.
Zurück zum Zitat Chang-Claude J, Kropp S, Jager B, Bartsch H, Risch A. Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:698–704.PubMed Chang-Claude J, Kropp S, Jager B, Bartsch H, Risch A. Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:698–704.PubMed
12.
Zurück zum Zitat van der Hel OL, Bueno-de-Mesquita HB, van Gils CH, Roest M, Slothouber B, Grobbee DE, et al. Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (the netherlands). Cancer Causes Control. 2005;16:675–81.CrossRefPubMed van der Hel OL, Bueno-de-Mesquita HB, van Gils CH, Roest M, Slothouber B, Grobbee DE, et al. Cumulative genetic defects in carcinogen metabolism may increase breast cancer risk (the netherlands). Cancer Causes Control. 2005;16:675–81.CrossRefPubMed
13.
Zurück zum Zitat Alberg AJ, Daudt A, Huang H, Hoffman SC, Comstock GW, Helzlsouer KJ, et al. N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer. Cancer Detect Prev. 2004;28:187–93.CrossRefPubMed Alberg AJ, Daudt A, Huang H, Hoffman SC, Comstock GW, Helzlsouer KJ, et al. N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer. Cancer Detect Prev. 2004;28:187–93.CrossRefPubMed
14.
Zurück zum Zitat Sillanpaa P, Hirvonen A, Kataja V, Eskelinen M, Kosma V, Uusitupa M, et al. NAT2 slow acetylator genotype as an important modifier of breast cancer risk. Int J Cancer. 2005;114:579–84.CrossRefPubMed Sillanpaa P, Hirvonen A, Kataja V, Eskelinen M, Kosma V, Uusitupa M, et al. NAT2 slow acetylator genotype as an important modifier of breast cancer risk. Int J Cancer. 2005;114:579–84.CrossRefPubMed
15.
Zurück zum Zitat Lissowska J, Brinton LA, Zatonski W, Blair A, Bardin-Mikolajczak A, Peplonska B, et al. Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int J Cancer. 2006;119:1961–9.CrossRefPubMed Lissowska J, Brinton LA, Zatonski W, Blair A, Bardin-Mikolajczak A, Peplonska B, et al. Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int J Cancer. 2006;119:1961–9.CrossRefPubMed
17.
Zurück zum Zitat Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, et al. Tobacco smoking and breast cancer risk: an evaluation based on a systematic review of epidemiological evidence in the Japanese population. Jpn J Clin Oncol. 2006;36:387–94.CrossRefPubMed Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, et al. Tobacco smoking and breast cancer risk: an evaluation based on a systematic review of epidemiological evidence in the Japanese population. Jpn J Clin Oncol. 2006;36:387–94.CrossRefPubMed
Metadaten
Titel
N-acetyltransferase 2 polymorphism and breast cancer risk with smoking: a case control study in Japanese women
verfasst von
Akio Hara
Naruto Taira
Taeko Mizoo
Keiko Nishiyama
Tomohiro Nogami
Takayuki Iwamoto
Takayuki Motoki
Tadahiko Shien
Junji Matsuoka
Hiroyoshi Doihara
Setsuko Ishihara
Hiroshi Kawai
Kensuke Kawasaki
Youichi Ishibe
Yutaka Ogasawara
Shinichiro Miyoshi
Publikationsdatum
11.04.2016
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 2/2017
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-016-0696-1

Weitere Artikel der Ausgabe 2/2017

Breast Cancer 2/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.